A. Catino

G. Serio, G. Pelosi, M. Papotti, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease

D. Galetta, R. Trisolini, S. Novello, 2018, The clinical respiratory journal.

Behaviour of Four Serum Tumor Markers in Pregnant Women

G. Gargano, M. Correale, I. Abbate, 1993, The International journal of biological markers.

Peripheral skin edema as unusual toxicity in three patients with advanced non-small cell lung cancer treated with pemetrexed alone or in combination with cisplatin.

D. Galetta, G. Colucci, N. Silvestris, 2011, Journal of Thoracic Oncology.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

L. Landi, C. Tibaldi, A. D’Incecco, 2014, Clinical lung cancer.

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

M. Filetti, L. Landi, J. Aerts, 2020, Journal for ImmunoTherapy of Cancer.

M. Filetti, L. Landi, F. Cappuzzo, 2020, Clinical lung cancer.

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

M. Filetti, L. Landi, F. Cappuzzo, 2020, Cancer Immunology, Immunotherapy.

M. Filetti, D. Galetta, V. Adamo, 2020, medRxiv.

Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of >= 50%.

M. Filetti, L. Landi, F. Cappuzzo, 2020, medRxiv.

DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.

V. Torri, V. Longo, D. Galetta, 2020, Clinical lung cancer.

EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.

V. Longo, D. Galetta, M. Bilancia, 2020, Clinical lung cancer.

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

M. Filetti, D. Galetta, G. Banna, 2019, Clinical and Translational Oncology.

miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome

D. Galetta, S. Tommasi, R. Lacalamita, 2016, Tumor Biology.

Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review

V. Longo, R. Massafra, D. Galetta, 2023, Journal of clinical medicine.

Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin.

V. Lorusso, A. Latorre, D. Sambiasi, 2003, Oncology reports.

Targeting Tumour Vascularization from Bench to Bedside: Suggestions for Combination with Hyperthermia

V. Fazio, G. Ranieri, C. Gadaleta, 2009 .

Psychological well-being in cancer outpatients during COVID-19.

V. Longo, D. Galetta, A. Guarini, 2021, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade

V. Longo, D. Galetta, A. Catino, 2022, Thoracic cancer.

Stop-flow perfusion with mitomycin-C as locoregional approach in the treatment of large-unresectable liver metastases.

C. Gadaleta, A. Catino, V. Mattioli, 2006, In vivo.

Radiofrequency ablation of 40 lung neoplasms: preliminary results.

G. Colucci, V. Lorusso, M. de Lena, 2004, AJR. American journal of roentgenology.

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

A. Rossi, G. Rossi, A. Ceribelli, 2017, Lung cancer.

Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non–Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases1

G. Serio, D. Galetta, S. Tommasi, 2018, Translational oncology.

Cyclophosphamide, Novantrone, Fluorouracil (CNF) + G-CSF Neo-Adjuvant chemotherapy in operable breast cancer

F. Schittulli, S. Longo, V. Lorusso, 1994 .

Breath Analysis: Comparison among Methodological Approaches for Breath Sampling

P. Barbieri, D. Galetta, G. de Gennaro, 2020, Molecules.

Fine Needle Aspiration Cytology: A Tool to Study NHERF1 Expression as a Potential Marker of Aggressiveness in Lung Cancer

Giovanni Simone, Anna Scattone, Domenico Galetta, 2015, Molecular Biotechnology.

Cancer, Heart Diseases, and Common Risk Factors: Smoke

D. Galetta, E. Montagna, A. Catino, 2017 .

Impact of tobacco control interventions on smoking initiation, cessation, and prevalence: a systematic review

V. Longo, D. Galetta, D. Bafunno, 2020, Journal of thoracic disease.

Tobacco control in Europe: A review of campaign strategies for teenagers and adults.

D. Galetta, D. Bafunno, A. Catino, 2019, Critical reviews in oncology/hematology.

ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients

G. Giaccone, E. Felip, R. Dziadziuszko, 2019, Annals of Oncology.

Mitoxantrone, L-Leucovorin and 5-Fluorouracil: An Effective and Well Tolerated First-Line Treatment for Advanced Breast Cancer

A. Paradiso, M. Guida, V. Lorusso, 1999, Tumori.

Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials

V. Longo, D. Galetta, Alessandro Rizzo, 2023, Thoracic cancer.

Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect?

V. Longo, D. Galetta, P. Gatti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.

M. Guida, G. Gargano, V. Lorusso, 2001, European journal of cancer.

Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report

S. Novello, A. Del Conte, R. Chiari, 2019, In Vivo.

Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results

V. Lorusso, M. Lena, M. Brandi, 1994 .

A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region

M. C. Comes, R. Massafra, D. Galetta, 2023, PloS one.

Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

F. Cappuzzo, J. Aerts, F. Mazzoni, 2021, Thoracic cancer.

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

M. Filetti, L. Landi, G. Minuti, 2021, Thoracic cancer.

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report

D. Galetta, S. Tommasi, R. Lacalamita, 2022, Diagnostics.

Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer

M. Guida, F. Schittulli, V. Lorusso, 2003, British Journal of Cancer.

Randomised Clinical Trial of Adjuvant Chemotherapy in Patients with Node-Negative, Fast-Proliferating Breast Cancer

A. Paradiso, F. Schittulli, S. Longo, 2012, Drugs.

Single-step therapy -- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies.

V. Fazio, G. Gadaleta-Caldarola, G. Ranieri, 2009, In vivo.

The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy.

D. Ribatti, G. Ranieri, C. Gadaleta, 2003, Oncology reports.

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement

V. Longo, D. Galetta, R. Lacalamita, 2020, JTO clinical and research reports.

circPVT1 and PVT1/AKT3 show a role in cell proliferation, apoptosis, and tumor subtype‐definition in small cell lung cancer

J. Kjems, A. Fatica, K. Kok, 2022, Genes, chromosomes & cancer.

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib

V. Longo, D. Galetta, A. Prelaj, 2021, Thoracic cancer.

Dose-Dense Primary Chemotherapy, as Part of Multidisciplinary Treatment, for Inoperable Stage III B Breast Cancer – Long-Term Results of a Phase II Trial

F. Atzori, L. Minerba, A. Contu, 2007, Oncology.

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.

M. Filetti, D. Mallardo, P. Ascierto, 2021, JAMA oncology.

Breast Metastasis from Malignant Pleural Mesothelioma: A Rare Challenging Entity.

D. Galetta, D. La Forgia, A. Scattone, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study

O. Nanni, R. Labianca, P. Tagliaferri, 2023, EClinicalMedicine.

Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review.

V. Fazio, R. Divella, A. Daniele, 2016, The international journal of biochemistry & cell biology.

Hypoxic stop-flow perfusion with mitomycin-C in the treatment of multifocal liver metastases. Usefulness of a vascular arterial stent to prevent iatrogenic lesions of the hepatic arterial wall.

G. Ranieri, C. Gadaleta, G. Console, 2003, Journal of experimental & clinical cancer research : CR.

Oral versus intravenous cmf in metastatic breast-cancer - a randomized study.

P. Ditonno, V. Lorusso, M. Brandi, 1994, International journal of oncology.

Role of the contrast-enhanced spectral mammography for the diagnosis of breast metastases from extramammary neoplasms.

S. Tangaro, R. Massafra, D. Galetta, 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

L. Landi, C. Tibaldi, A. D’Incecco, 2014, Clinical lung cancer.

Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go

V. Longo, A. Nardone, E. Montagna, 2024, International journal of molecular sciences.